|Bid||155.61 x 100|
|Day's Range||163.58 - 164.69|
|52 Week Range||128.86 - 167.10|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.25%|
Small-cap stocks are getting really expensive and that could weigh on the related ETFs.
Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.
The iShares Russell 1000 Growth ETF is up 9.9% in 2017 as of Monday’s close, while the iShares Russell 1000 Value ETF has gained 2.6%. A FTSE Russell analyst has addressed what it means.